Definition of resistance and intolerance to hydroxyurea in patients with PV, according to the ELN consensus
| Resistance and intolerance to hydroxyurea in patients with PV: ELN consensus . |
|---|
| 1. Need for phlebotomy to keep hematocrit <45% after 3 mo of at least 2 g per day of hydroxycarbamide, OR |
| 2. Uncontrolled myeloproliferation, ie, platelet count >400 × 109/L AND white blood cell count >10 × 109/L after 3 mo of at least 2 g per day of hydroxycarbamide, OR |
| 3. Failure to reduce massive splenomegaly (ie, extending >10 cm from the left costal margin) by >50% as measured by palpation, OR failure to completely relieve symptoms related to splenomegaly, after 3 mo of at least 2 g per day of hydroxycarbamide, OR |
| 4. Absolute neutrophil count <1.0 × 109/L OR platelet count <100 × 109/L or hemoglobin <100 g/L at the lowest dose of hydroxycarbamide required to achieve a complete or partial clinicohematological response,* OR |
| 5. Presence of leg ulcers or other unacceptable hydroxycarbamide-related nonhematological toxicities, such as mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis, or fever at any dose of hydroxycarbamide |
| Resistance and intolerance to hydroxyurea in patients with PV: ELN consensus . |
|---|
| 1. Need for phlebotomy to keep hematocrit <45% after 3 mo of at least 2 g per day of hydroxycarbamide, OR |
| 2. Uncontrolled myeloproliferation, ie, platelet count >400 × 109/L AND white blood cell count >10 × 109/L after 3 mo of at least 2 g per day of hydroxycarbamide, OR |
| 3. Failure to reduce massive splenomegaly (ie, extending >10 cm from the left costal margin) by >50% as measured by palpation, OR failure to completely relieve symptoms related to splenomegaly, after 3 mo of at least 2 g per day of hydroxycarbamide, OR |
| 4. Absolute neutrophil count <1.0 × 109/L OR platelet count <100 × 109/L or hemoglobin <100 g/L at the lowest dose of hydroxycarbamide required to achieve a complete or partial clinicohematological response,* OR |
| 5. Presence of leg ulcers or other unacceptable hydroxycarbamide-related nonhematological toxicities, such as mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis, or fever at any dose of hydroxycarbamide |
Complete response was defined as: hematocrit <45% without phlebotomy, platelet count <400 × 109/L, white blood cell count <10 × 109/L, and no disease-related symptoms. Partial response was defined as: hematocrit <45% without phlebotomy, or response in 3 or more of the other criteria.